https://de.marketscreener.com/kurs/aktie/MORPHOSYS-AG-436425/news/MorphoSys-meldet-dass-Lizenzpartner-Janssen-berichtet-hat-dass-Tremfya-R-die-langfristigen-Therap-27253311/?utm_source=telegram&utm_medium=social&utm_campaign=share